<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32103957</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1176-6328</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>16</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Neuropsychiatric disease and treatment</Title>
          <ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review.</ArticleTitle>
        <Pagination>
          <StartPage>369</StartPage>
          <EndPage>379</EndPage>
          <MedlinePgn>369-379</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S185774</ELocationID>
        <Abstract>
          <AbstractText>Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset, developmental epileptic encephalopathy, with different etiologies and co-morbidities. Seizure treatment in LGS represents a major challenge; new antiepileptic drugs (AEDs) are developed to especially address seizures resulting in high morbidity and mortality, such as drop seizures. Rufinamide (RFN) is one of the latest AEDs licensed for patients with LGS. Its mechanism of action involves sodium channels in a way that is unrelated to other AEDs. Here we discuss the use of adjunctive RFN in children and adolescents with LGS and its efficacy and safety profile, based on a systematic literature review. RFN shows a very favorable profile in terms of adverse events and drug-interactions in children. It is particularly effective on tonic-atonic seizures and spasms, impacting on the quality of life of the patients. Further studies are needed to clarify the interaction profile with the newest AEDs for LGS and to assess correlations between the etiology of LGS and drug response to individualize treatment and maximize efficacy.</AbstractText>
          <CopyrightInformation>© 2020 Balagura et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Balagura</LastName>
            <ForeName>Ganna</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Neurology and Muscular Diseases Unit, IRCCS 'G. Gaslini' Institute, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riva</LastName>
            <ForeName>Antonella</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Neurology and Muscular Diseases Unit, IRCCS 'G. Gaslini' Institute, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchese</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-1977-9275</Identifier>
            <AffiliationInfo>
              <Affiliation>Pediatric Neurology and Muscular Diseases Unit, IRCCS 'G. Gaslini' Institute, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verrotti</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of L'Aquila, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Striano</LastName>
            <ForeName>Pasquale</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-6065-1476</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Neurology and Muscular Diseases Unit, IRCCS 'G. Gaslini' Institute, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neuropsychiatr Dis Treat</MedlineTA>
        <NlmUniqueID>101240304</NlmUniqueID>
        <ISSNLinking>1176-6328</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lennox-Gastaut</Keyword>
        <Keyword MajorTopicYN="N">children</Keyword>
        <Keyword MajorTopicYN="N">epilepsy</Keyword>
        <Keyword MajorTopicYN="N">rufinamide</Keyword>
      </KeywordList>
      <CoiStatement>P.S. has received speaker fees and participated at advisory boards for Biomarin, Zogenyx, and GW Pharmaceuticals, and has received research funding from ENECTA srl, GW Pharmaceuticals, Kolfarma srl., and Eisai.  The authors report no other conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32103957</ArticleId>
        <ArticleId IdType="pmc">PMC7008198</ArticleId>
        <ArticleId IdType="doi">10.2147/NDT.S185774</ArticleId>
        <ArticleId IdType="pii">185774</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aicardi J, Levy Gomes A. Clinical and electroencephalographic symptomatology of the ‘genuine’ lennox-gastaut syndrome and its differentiation from other forms of epilepsy of early childhood. Epilepsy Res Suppl. 1992;6:185–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1418482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51:676–685. doi:10.1111/j.1528-1167.2010.02522.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2010.02522.x</ArticleId>
            <ArticleId IdType="pubmed">20196795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asadi-Pooya AA. Lennox-gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39:403. doi:10.1007/s10072-017-3188-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-017-3188-y</ArticleId>
            <ArticleId IdType="pubmed">29124439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arzimanoglou A, Ferreira J, Satlin A, et al. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to &lt;4 years old) with lennox-gastaut syndrome: final results from randomized study 303. Eur J Paediatr Neurol. 2019;23(1):126–135. doi:10.1016/j.ejpn.2018.09.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2018.09.010</ArticleId>
            <ArticleId IdType="pubmed">30309816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res. 1995;12(12):1878–1882. doi:10.1023/A:1016275402723</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1016275402723</ArticleId>
            <ArticleId IdType="pubmed">8786960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with lennox-gastaut syndrome. Neurology. 2008;70(21):1950–1958. doi:10.1212/01.wnl.0000303813.95800.0d</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000303813.95800.0d</ArticleId>
            <ArticleId IdType="pubmed">18401024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008;49(7):1213–1220. doi:10.1111/j.1528-1167.2008.01552.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1528-1167.2008.01552.x</ArticleId>
            <ArticleId IdType="pubmed">18325020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilchrist J, Dutton S, Diaz-Bustamante M. Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents. ACS Chem Biol. 2014;9:1204–1212. doi:10.1021/cb500108p</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cb500108p</ArticleId>
            <ArticleId IdType="pmc">PMC4027953</ArticleId>
            <ArticleId IdType="pubmed">24635129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–1141. doi:10.1111/epi.2008.49.issue-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.2008.49.issue-7</ArticleId>
            <ArticleId IdType="pubmed">18503564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephen JL, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011;25(2):89–107. doi:10.2165/11584860-000000000-00000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11584860-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">21254787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inovelon® Summary of Product Characteristics. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Yıldız EP, Hızlı Z, Bektaş G, et al. Efficacy of rufinamide in childhood refractory epilepsy. Turk J Pediatr. 2018;60(3):238–243. doi:10.24953/turkjped.2018.03.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24953/turkjped.2018.03.002</ArticleId>
            <ArticleId IdType="pubmed">30511535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JY, Lee CG, Yu HJ, Nam SH, Lee J, Lee M. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res. 2012;2(2):33–37. doi:10.14581/jer.12009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14581/jer.12009</ArticleId>
            <ArticleId IdType="pmc">PMC3952322</ArticleId>
            <ArticleId IdType="pubmed">24649460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson HE, Loddenkemper T, Vendrame M, et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011;20(2):344–348. doi:10.1016/j.yebeh.2010.11.023</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2010.11.023</ArticleId>
            <ArticleId IdType="pubmed">21233024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in lennox-gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3):202–208. doi:10.1111/j.1600-0404.2010.01334.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2010.01334.x</ArticleId>
            <ArticleId IdType="pubmed">20199521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14(3):491–495. doi:10.1016/j.yebeh.2008.12.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2008.12.013</ArticleId>
            <ArticleId IdType="pubmed">19162229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatr Neurol. 2010;43(3):155–158. doi:10.1016/j.pediatrneurol.2010.04.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pediatrneurol.2010.04.003</ArticleId>
            <ArticleId IdType="pubmed">20691934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cusmai R, Verrotti A, Moavero R, et al. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Res. 2014;108(3):542–546. doi:10.1016/j.eplepsyres.2014.01.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2014.01.013</ArticleId>
            <ArticleId IdType="pubmed">24548548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with lennox-gastautsyndrome: first Italianmulticenterexperience. Seizure. 2010;19(9):587–591. doi:10.1016/j.seizure.2010.09.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2010.09.008</ArticleId>
            <ArticleId IdType="pubmed">20888268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabriela O, Bozarth XL. Rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy: a retrospective single center study. Epilepsy Res. 2019;106211. doi:10.1016/j.eplepsyres.2019.106211</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2019.106211</ArticleId>
            <ArticleId IdType="pubmed">31575436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–1592. doi:10.1111/epi.13852</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.13852</ArticleId>
            <ArticleId IdType="pubmed">28782097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for lennox-gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–1636. doi:10.1016/j.eplepsyres.2014.08.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2014.08.019</ArticleId>
            <ArticleId IdType="pubmed">25219353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Long-term safety and seizure outcome in Japanese patients with lennox-gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial. Epilepsy Res. 2016;121:1–7. doi:10.1016/j.eplepsyres.2016.01.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2016.01.002</ArticleId>
            <ArticleId IdType="pubmed">26827266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thome-Souza S, Kadish NE, Ramgopal S, et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia. 2014;55(8):1235–1244. doi:10.1111/epi.12689</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.12689</ArticleId>
            <ArticleId IdType="pubmed">25070475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arzimanoglou A, Ferreira JA, Satlin A, et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with lennox-gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol. 2016;20(3):393–402. doi:10.1016/j.ejpn.2015.12.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2015.12.015</ArticleId>
            <ArticleId IdType="pubmed">26805435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Kang HC, Lee JS, Kim HD. Rufinamide efficacy and safety in children aged 1–4 years with lennox-gastaut syndrome. Brain Dev. 2018;40(10):897–903. doi:10.1016/j.braindev.2018.07.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.braindev.2018.07.020</ArticleId>
            <ArticleId IdType="pubmed">30166208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Lee JH, Ryu HW, et al. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalized epilepsy. Epileptic Disord. 2013;15(1):49–54. doi:10.1684/epd.2013.0557</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/epd.2013.0557</ArticleId>
            <ArticleId IdType="pubmed">23531645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SH, Eun SH, Kang HC, et al. Rufinamide as an adjuvant treatment in children with lennox-gastautsyndrome. Seizure. 2012;21(4):288–291. doi:10.1016/j.seizure.2012.02.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2012.02.006</ArticleId>
            <ArticleId IdType="pubmed">22421185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee EH, Yum MS, Ko TS. Effectiveness and tolerability of rufinamide in children and young adults with lennox-gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg. 2013;115(7):926–929. doi:10.1016/j.clineuro.2012.09.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2012.09.021</ArticleId>
            <ArticleId IdType="pubmed">23083943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17(4):546–548. doi:10.1016/j.yebeh.2010.01.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2010.01.005</ArticleId>
            <ArticleId IdType="pubmed">20185372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikanorova M, Brandt C, Auvin S, McMurray R. Real-world data on rufinamidetreatment in patients with lennox-gastaut syndrome: results from a Europeannoninterventional registry study. Epilepsy Behav. 2017;76:63–70. doi:10.1016/j.yebeh.2017.08.026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2017.08.026</ArticleId>
            <ArticleId IdType="pubmed">28927712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Striano P, McMurray R, Santamarina E, Falip M. Rufinamide for the treatment of lennox-gastaut syndrome: evidence from clinical trials and clinical practice. Epileptic Disord. 2018;20(1):13–29. doi:10.1684/epd.2017.0950</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1684/epd.2017.0950</ArticleId>
            <ArticleId IdType="pubmed">29313492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with dravet syndrome. Epilepsy Behav. 2011;21(3):282–284. doi:10.1016/j.yebeh.2011.04.057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2011.04.057</ArticleId>
            <ArticleId IdType="pubmed">21620771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auvin S, Williams B, McMurray R, Kumar D, Perdomo C, Malhotra M. Novel seizure outcomes in patients with lennox‐gastaut syndrome: post hoc analysis of seizure‐free days in rufinamide study 303. Epilepsia Open. 2019;4:275–280. doi:10.1002/epi4.12314</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/epi4.12314</ArticleId>
            <ArticleId IdType="pmc">PMC6546073</ArticleId>
            <ArticleId IdType="pubmed">31168494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panebianco M 1, Prabhakar H, Marson AG. Rufinamide add-on therapy for refractory epilepsy. Cochrane Database Syst Rev. 2018;4:CD011772. doi:10.1002/14651858.CD011772.pub2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD011772.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6494418</ArticleId>
            <ArticleId IdType="pubmed">29691835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rufinamide. Dermatol Online J. 2013;19(4):4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24021364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chambel M, Mascarenhas MI, Regala J, Gouveia C, Prates S. Clinical Stevens-Johnson syndrome and rufinamide: a clinical case. Allergol Immunopathol (Madr). 2013;41(1):68–69. doi:10.1016/j.aller.2011.12.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.aller.2011.12.004</ArticleId>
            <ArticleId IdType="pubmed">22306278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767–778. doi:10.1517/14740338.2012.705828</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14740338.2012.705828</ArticleId>
            <ArticleId IdType="pubmed">22794330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;9(5):776–781. doi:10.1016/j.hrthm.2012.01.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.hrthm.2012.01.006</ArticleId>
            <ArticleId IdType="pmc">PMC3482382</ArticleId>
            <ArticleId IdType="pubmed">22245794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Zhao H, Chen Z. The efficacy and safety of rufinamide in drug-resistant epilepsy: a meta-analysis of double-blind, randomized, placebo controlled trials. Epilepsy Res. 2016;120:104–110. doi:10.1016/j.eplepsyres.2016.01.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2016.01.001</ArticleId>
            <ArticleId IdType="pubmed">26811934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epidiolex. Summary of Product Characteristics. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Lagae L, Schoonjans AS, Gammaitoni AR, Galer BS, Ceulemans B. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in lennox-gastaut syndrome. Epilepsia. 2018;59(10):1881–1888. doi:10.1111/epi.14540</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/epi.14540</ArticleId>
            <ArticleId IdType="pubmed">30146701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A study to investigate the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution in children and adults with epileptic encephalopathy including dravet syndrome and lennox-gastaut syndrome. ClinicalTrials.gov Identifier: NCT03936777.</Citation>
        </Reference>
        <Reference>
          <Citation>McMurray R, Striano P. Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016;5(1):35–43. doi:10.1007/s40120-016-0041-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40120-016-0041-9</ArticleId>
            <ArticleId IdType="pmc">PMC4919131</ArticleId>
            <ArticleId IdType="pubmed">26861566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grosso S, Coppola G, Dontin SD, et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol. 2014;18(5):641–645. doi:10.1016/j.ejpn.2014.05.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2014.05.001</ArticleId>
            <ArticleId IdType="pubmed">24912730</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
